The clinical efficacy of hydrogen combined with tetrandrine in the treatment of silicosis fibrosis: A randomized controlled intervention study.
Kang Xiao, Yanping Sang, Mao Cao, Yong Yang, Mengjie Cheng, Jiazi Ma, Siqi Wang, Xinyue Li, Xuansheng Ding, Zhongjun Du · Respiratory medicine · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 116 patients with stage II silicosis, H₂ combined with Tet was more effective than Tet alone in the treatment of stage II silicosis. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 116 patients with stage II silicosis. H₂ combined with Tet was more effective than Tet alone in the treatment of stage II silicosis.
What the Researchers Studied
The researchers studied 116 patients with stage II silicosis. The study used a randomized, double-blind human clinical trial.
What Effects Did Molecular Hydrogen Have?
The assessed outcomes included pulmonary function, exercise tolerance, clinical symptoms, and serum interleukin-6 (IL-6) levels following treatment with Tet alone or Tet combined with H₂ inhalation. H₂ combined with Tet was more effective than Tet alone in the treatment of stage II silicosis.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 116 patients with stage II silicosis. The reported sample size was 116. The study used a randomized, double-blind human clinical trial.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.